ProQR Therapeutics N.V. Research and Development Expense
ProQR Therapeutics N.V. (PRQR) reported Research and Development Expense of EUR 44.73 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2026-03-12
- ProQR Therapeutics N.V. research and development expense for the quarter ending 2025-12-31 was 9.92M EUR, a 6.49% decline year-over-year.
- ProQR Therapeutics N.V. research and development expense for the quarter ending 2025-09-30 was 11.08M EUR, a 17.70% increase year-over-year.
- ProQR Therapeutics N.V. research and development expense for the quarter ending 2025-06-30 was 11.41M EUR, a 61.86% increase year-over-year.
- ProQR Therapeutics N.V. research and development expense for the quarter ending 2025-03-31 was 12.32M EUR, a 32.75% increase year-over-year.
| Period end | Research And Development Expense 3 month | Research And Development Expense 6 month | Research And Development Expense 9 month | Research And Development Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | 9.92M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-03-12 | 21.00M EUR derived: sum of 2 quarters · filed 2026-03-12 | 32.41M EUR derived: sum of 3 quarters · filed 2026-03-12 | 44.73M EUR 20-F · filed 2026-03-12 |
| 2025-09-30 | 11.08M EUR 6-K · filed 2025-11-06 | 22.49M EUR derived: sum of 2 quarters · filed 2025-11-06 | 34.81M EUR 6-K · filed 2025-11-06 | 45.42M EUR derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | 11.41M EUR 6-K · filed 2025-08-07 | 23.73M EUR 6-K · filed 2025-08-07 | 34.34M EUR derived: sum of 3 quarters · filed 2026-03-12 | 43.76M EUR derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | 12.32M EUR 6-K · filed 2025-05-08 | 22.93M EUR derived: sum of 2 quarters · filed 2026-03-12 | 32.35M EUR derived: sum of 3 quarters · filed 2026-03-12 | 39.40M EUR derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | 10.61M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-03-12 | 20.02M EUR derived: sum of 2 quarters · filed 2026-03-12 | 27.07M EUR derived: sum of 3 quarters · filed 2026-03-12 | 36.36M EUR 20-F · filed 2026-03-12 |
| 2024-09-30 | 9.41M EUR 6-K · filed 2025-11-06 | 16.46M EUR derived: sum of 2 quarters · filed 2025-11-06 | 25.75M EUR 6-K · filed 2025-11-06 | 33.48M EUR derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | 7.05M EUR 6-K · filed 2025-08-07 | 16.33M EUR 6-K · filed 2025-08-07 | 24.06M EUR derived: sum of 3 quarters · filed 2026-03-12 | 29.51M EUR derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | 9.28M EUR 6-K · filed 2025-05-08 | 17.02M EUR derived: sum of 2 quarters · filed 2026-03-12 | 22.46M EUR derived: sum of 3 quarters · filed 2026-03-12 | 28.37M EUR derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | 7.73M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-03-12 | 13.18M EUR derived: sum of 2 quarters · filed 2026-03-12 | 19.09M EUR derived: sum of 3 quarters · filed 2026-03-12 | 25.15M EUR 20-F · filed 2026-03-12 |
| 2023-09-30 | 5.45M EUR 6-K · filed 2024-11-07 | 11.36M EUR derived: sum of 2 quarters · filed 2024-11-07 | 17.41M EUR 6-K · filed 2024-11-07 | 28.11M EUR derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | 5.91M EUR 6-K · filed 2024-08-08 | 11.97M EUR 6-K · filed 2024-08-08 | 22.67M EUR derived: sum of 3 quarters · filed 2025-03-13 | 38.02M EUR derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | 6.06M EUR 6-K · filed 2024-05-09 | 16.76M EUR derived: sum of 2 quarters · filed 2025-03-13 | 32.11M EUR derived: sum of 3 quarters · filed 2025-03-13 | 43.56M EUR derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | 10.70M EUR derived: 20-F 12 month − 6-K 9 month · filed 2025-03-13 | 26.05M EUR derived: sum of 2 quarters · filed 2025-03-13 | 37.50M EUR derived: sum of 3 quarters · filed 2025-03-13 | 50.87M EUR 20-F · filed 2025-03-13 |
| 2022-09-30 | 15.35M EUR 6-K · filed 2023-11-07 | 26.80M EUR derived: sum of 2 quarters · filed 2023-11-07 | 40.17M EUR 6-K · filed 2023-11-07 | 52.62M EUR derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | 11.45M EUR 6-K · filed 2023-08-03 | 24.82M EUR 6-K · filed 2023-08-03 | 37.27M EUR derived: sum of 3 quarters · filed 2023-08-03 | 48.40M EUR derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | 13.37M EUR 6-K · filed 2023-05-16 | 25.82M EUR derived: sum of 2 quarters · filed 2023-05-16 | 36.95M EUR derived: sum of 3 quarters · filed 2023-05-16 | 46.68M EUR derived: sum of 4 quarters · filed 2023-05-16 |
| 2021-12-31 | 12.46M EUR 6-K · filed 2022-02-24 | 23.58M EUR derived: sum of 2 quarters · filed 2022-11-09 | 33.31M EUR derived: sum of 3 quarters · filed 2022-11-09 | 42.22M EUR 20-F · filed 2024-03-13 |
| 2021-09-30 | 11.12M EUR 6-K · filed 2022-11-09 | 20.86M EUR derived: sum of 2 quarters · filed 2022-11-09 | 29.76M EUR 6-K · filed 2022-11-09 | 38.18M EUR derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | 9.73M EUR 6-K · filed 2022-08-04 | 18.64M EUR 6-K · filed 2022-08-04 | 27.06M EUR derived: sum of 3 quarters · filed 2022-08-04 | 35.36M EUR derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | 8.90M EUR 6-K · filed 2022-05-05 | 17.32M EUR derived: sum of 2 quarters · filed 2022-05-05 | 25.63M EUR derived: sum of 3 quarters · filed 2022-05-05 | 34.22M EUR derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | 8.42M EUR 6-K · filed 2022-02-24 | 16.72M EUR derived: sum of 2 quarters · filed 2022-02-24 | 25.31M EUR derived: sum of 3 quarters · filed 2022-02-24 | 38.13M EUR 20-F · filed 2023-03-29 |
| 2020-09-30 | 8.30M EUR 6-K · filed 2021-11-04 | 16.89M EUR derived: sum of 2 quarters · filed 2021-11-04 | 29.72M EUR 6-K · filed 2021-11-04 | 43.65M EUR derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | 8.59M EUR 6-K · filed 2021-08-05 | 21.41M EUR 6-K · filed 2021-08-05 | 35.34M EUR derived: sum of 3 quarters · filed 2021-08-05 | 46.42M EUR derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | 12.82M EUR 6-K · filed 2020-05-07 | 26.76M EUR derived: sum of 2 quarters · filed 2021-02-25 | 37.83M EUR derived: sum of 3 quarters · filed 2021-02-25 | 47.35M EUR derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-12-31 | 13.93M EUR 6-K · filed 2021-02-25 | 25.00M EUR derived: sum of 2 quarters · filed 2021-02-25 | 34.53M EUR derived: sum of 3 quarters · filed 2021-02-25 | 46.49M EUR 20-F · filed 2022-04-29 |
| 2019-09-30 | 11.07M EUR 6-K · filed 2020-11-16 | 20.60M EUR derived: sum of 2 quarters · filed 2020-11-16 | 32.56M EUR 6-K · filed 2020-11-16 | 42.10M EUR derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-06-30 | 9.52M EUR 6-K · filed 2020-08-06 | 21.49M EUR 6-K · filed 2020-08-06 | 31.03M EUR derived: sum of 3 quarters · filed 2021-03-24 | 37.33M EUR derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-03-31 | 11.96M EUR 6-K · filed 2020-05-07 | 21.50M EUR derived: sum of 2 quarters · filed 2021-03-24 | 27.80M EUR derived: sum of 3 quarters · filed 2021-03-24 | 33.79M EUR derived: sum of 4 quarters · filed 2021-03-24 |
| 2018-12-31 | 9.54M EUR derived: 20-F 12 month − 6-K 9 month · filed 2021-03-24 | 15.84M EUR derived: sum of 2 quarters · filed 2021-03-24 | 21.83M EUR derived: sum of 3 quarters · filed 2021-03-24 | 29.51M EUR 20-F · filed 2021-03-24 |
| 2018-09-30 | 6.30M EUR 6-K · filed 2019-11-12 | 12.29M EUR derived: sum of 2 quarters · filed 2019-11-12 | 19.97M EUR 6-K · filed 2019-11-12 | |
| 2018-06-30 | 5.99M EUR 6-K · filed 2019-08-07 | 13.68M EUR 6-K · filed 2019-08-07 | ||
| 2017-12-31 | 31.15M EUR 20-F · filed 2020-03-31 | |||
| 2017-06-30 | 7.55M EUR 6-K · filed 2018-08-08 | 15.58M EUR 6-K · filed 2018-08-08 | ||
| 2016-12-31 | 31.92M EUR 20-F · filed 2019-03-28 | |||
| 2015-12-31 | 23.40M EUR 20-F · filed 2018-03-30 |